WINREVAIR
GrowthBLAINJECTIONINJECTABLEPriority Review
Approved
Mar 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
WINREVAIR (sotatercept-csrk) is a Merck-sponsored biologic approved March 26, 2024, via Biologics License Application (BLA). The mechanism of action and specific indications are not yet disclosed in available data, but the injectable formulation suggests a protein therapeutic. The product is in early growth phase as a newly launched biologic.
Growth
Early-stage growth trajectory with competitive pressure at 30% intensity signals a focused commercial team building market presence and establishing initial prescriber relationships.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Merck & Co. is hiring 1 role related to this product
Worked on WINREVAIR at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.